Member Directory - Jain Foundation

Member DirectoryJain Foundation2021-05-27T17:30:29+00:00

Isabelle Richard, PhD, Généthon (Evry, France)

Dr. Richard is the Research Director at the CNRS and the Head of the "Limb-Girdle Muscular Dystrophies" lab in Généthon (Evry, France).

Morayma Reyes, MD, PhD, University Of Washington (Seattle, WA)

Dr. Reyes is an Assistant Professor in the Department of Pathology and Laboratory Medicine, University of Washington (Seattle, WA).

Thomas Rando, MD, PhD, Stanford University (Palo Alto, CA)

Dr. Rando is Associate Professor in the Department of Neurology at the Stanford University School of Medicine and Chief of Neurology at the Palo Alto VA Medical Center (Palo Alto, CA).

Lorenzo Puri, MD, IRCCS Fondazione Santa LuciaLorenzo Puri, MD, IRCCS Fondazione Santa Lucia

Dr. Lorenzo Puri is Lab Director at IRCCS Fondazione Santa Lucia.

Terence Partridge, PhD, Children's National Medical Center (Washington, DC)

Dr. Partridge is a Principal Investigator in the Children's Research Institute Center for Genetic Medicine Research (CGMR) and a Professor of Pediatrics at the George Washington University School of Medicine and Health Sciences (Washington, DC).

Kanneboyina Nagaraju, DVM, PhD, Children's National Medical Center (Washington, DC)

Dr. Nagaraju is an associate Professor of Pediatrics and the director of the Murine Drug testing facility at the CNMC (Washington DC).

Vincent Mouly, PhD, Institut De Myologie (Paris, France)

Dr. Mouly is a member of the Remodeling, Regeneration and Cell Therapy of Striated Muscle team at the Institut de Myologie (Paris, France).

Steven Moore, MD, PhD, University Of Iowa (Iowa City, IA)

Dr. Moore is a professor of Neuropathology in the Department of Pathology at the University of Iowa (Iowa City, IA).

Jeffery Molkentin, PhD, Children’s Hospital, University Of Cincinnati (Cincinnati, OH)

Dr. Molkentin is a Professor in the Department of Pediatrics at the Children’s Hospital Medical Center, of the University of Cincinnati (Cincinnati, OH).

keyboard_arrow_left 1 2 3 4 5 … 10 keyboard_arrow_right

Bla/J mice (B6.A-Dysf^prmd/GeneJ)

Availability:
The Jackson Laboratory
Stock number: 012767
Strain information: http://jaxmice.jax.org/strain/012767.html
Phone: 800-422-MICE (800-422-6423)
610 Main Street, Bar Harbor, Maine 04609 USA

Please note that this strain has been cryopreserved by the Jackson Laboratories, but the Jain Foundation maintains a private colony of these mice for public use. To obtain these mice, please contact the Jain Foundation:

Jain Foundation Inc.
9706 Fourth Ave NE, Suite 101
Seattle, Washington 98115
Phone: 425-882-1492
Fax: 425-882-1050

Email: admin@jain-foundation.org

Development:
In these mice the progressive muscular dystrophy (prmd) allele from the A/J inbred strain is crossed onto the C57BL/6 genetic background. The cross was performed in the laboratory of Dr. Isabelle Richard at Genethon and the backcross generation reached N8. In collaboration with the Jain Foundation, Dr. Richard donated the strain to The Jackson Laboratory in 2010. Upon arrival, mice were bred to C57BL/6J for at least 2 generations to establish the colony.

Mutation:
An ETn retrotransposon (5-6kb) is inserted in intron 4 of the dysferlin gene.

Symptoms:
Disease onset is observed by 2 months and is characterized by the presence of centronucleated fibers and areas of inflammation. As seen with the original background A/J, mice homozygous for the prmd allele on the C57BL/6J background display an increasing number of centronucleated fibers and impairment in the majority of muscles by 4 months of age. In order of severity, the most affected muscles are psoas, quadriceps femoris, tibialis anterior, and gastrocnemius. Mice exhibit a decreased membrane repair capacity following laser wounding experiments. In an open space assay, mice cover less distance and are less active than wild-type. Mice that are homozygous for this allele are viable, fertile and normal in size.

Comparison with other disease strains:
Disease progression is similar to A/J: slightly slower than in SJL/J, Dysf-/- (Campbell), Dysf-/- (Brown), and C57BL/10.SJL mice. As in both SJL/J and Dysf-/- (Brown) mice, proximal muscles are more severely affected than distal muscles. As in Dysf-/- (Brown) mice, abdominal muscles are also affected.

Control strain(s):
C57BL/6 (for homozygotes); littermates (for heterozygotes).

References:
Lostal W; Bartoli M; Bourg N; Roudaut C; Bentaib A; Miyake K; Guerchet N; Fougerousse F; McNeil P; Richard I. 2010. Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer. Hum Mol Genet 19(10):1897-907.

PMID: 20154340

Below is a quick summary of the inclusion/exclusion criteria. Please review this information carefully prior to making any decision regarding participating.

Inclusion Criteria:

Must be Non-ambulant (cannot walk 10 meters in ≤ 30 sec) and age 18 years or older
Established mutations of the dysferlin gene on both alleles
Impaired muscle function but with sufficient muscle preservation to ensure muscle transfection based on magnetic resonance image of the EDB showing sufficient muscle preservation to permit transfection
Willingness of sexually active subjects with reproductive capacity to practice reliable method of contraception (If appropriate), during the first six months after gene transfer (females) or until two negative sperm samples are obtained post gene transfer (males).

Exclusion Criteria:

Active viral infection based on clinical observations or serological evidence of HIV, or Hepatitis A, B or C infection
The presence of dysferlin mutations without weakness or loss of function
Symptoms or signs of cardiomyopathy, including:
Dyspnea on exertion, pedal edema, shortness of breath upon lying flat, or rales at the base of the lungs
Echocardiogram with ejection fraction below 40%
Diagnosis of (or ongoing treatment for) an autoimmune disease
Persistent leukopenia or leukocytosis (WBC ≤ 3.5 K/µL or ≥ 20.0 K/µL) or an absolute neutrophil count < 1.5K/µL
Concomitant illness or requirement for chronic drug treatment that in the opinion of the PI creates unnecessary risks for gene transfer
Pregnancy
AAVrh74 or AAV8 binding antibody titers > 1:50 as determined by ELISA immunoassay
Abnormal laboratory values in the clinically significant range in the table below, based upon normal values in the Nationwide Children's Hospital Laboratory: GGT, Total Bilirubin, Cystatine, Hemoglobin, White Blood Cells
This first phase of the trial will be small and will only evaluate safety; patients enrolled are not expected to show improvement in their symptoms. If the initial trial is successful, a Phase 2 trial will be scheduled, which will look for efficacy (improvement in symptoms) as well as safety. Each phase would include more patients. So, it is a process and we are pacing ourselves as we support this major milestone in the field of therapeutic intervention for people suffering from dysferlinopathy.